BioCardia (NASDAQ:BCDA) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of BioCardia (NASDAQ:BCDA) in a report released on Friday, Benzinga reports. They currently have a $4.00 price target on the stock. HC Wainwright also issued estimates for BioCardia’s Q2 2024 earnings at ($0.10) EPS, Q3 2024 earnings at ($0.11) EPS, Q4 2024 earnings at ($0.16) EPS and FY2028 earnings at $0.27 EPS.

BioCardia Price Performance

Shares of BCDA opened at $3.17 on Friday. The stock’s 50-day moving average is $3.60 and its two-hundred day moving average is $5.41. The stock has a market cap of $5.77 million, a PE ratio of -0.45 and a beta of 1.37. BioCardia has a 12 month low of $2.62 and a 12 month high of $23.25.

BioCardia (NASDAQ:BCDA) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($1.35) EPS for the quarter. The company had revenue of $0.06 million for the quarter. BioCardia had a negative return on equity of 3,638.68% and a negative net margin of 2,208.76%. During the same quarter in the previous year, the company posted ($2.55) EPS. On average, research analysts anticipate that BioCardia will post -6.3 earnings per share for the current year.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its leading product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.